			Home About us Contact

Derivative Used (derivative + used)

Distribution by Scientific Domains

Medical Sciences	50%

Selected Abstracts

An Inexpensive Carbohydrate Derivative Used as a Chiral Auxiliary in the Synthesis of ,-Hydroxy Carboxylic Acids.

CHEMINFORM, Issue 5 2003
Hongwu Yu
Abstract For Abstract see ChemInform Abstract in Full Text. [source]

Allergic contact dermatitis from modified colophonium in wound dressings

CONTACT DERMATITIS, Issue 1 2007
Teresa M. Pereira
This study concerns a 69-year-old female patient with a longstanding history of venous ulcerations on both lower legs and multiple sensitivities, who developed eczematous lesions with the hydrocolloid dressing Combiderm® (Convatec Ltd., a Bristol-Myers Squibb division, Ickenham, Middlesex, UK). Epicutaneous tests were positive to this dressing and to a modified colophonium derivative, i.e. glyceryl rosinate, however not to the unmodified colophonium from the standard series. A review of the literature showed several case reports about sensitization to similar hydrocolloids being distributed under various brand names in different countries and which contain the pentaerythritol ester of the hydrogenated rosin as the tackifying agent. Some of the patients described did, while others did not, react to colophonium but only to a modified derivative. In our patient, the reaction to glyceryl rosinate most probably represent cross-sensitivity with the modified colophonium derivative used in Combiderm®, the presence (but not the exact nature) of which was showed by the company. In patients where allergic contact dermatitis from hydrocolloid dressings is strongly suspected and colophonium tests negatively, patch testing to modified colophonium derivatives should therefore be performed. As the complete composition of wound dressings is most often unknown, we urgently advocate legal requirements for labelling of those and in fact all medically used devices. [source]

Material Solubility-Photovoltaic Performance Relationship in the Design of Novel Fullerene Derivatives for Bulk Heterojunction Solar Cells

ADVANCED FUNCTIONAL MATERIALS, Issue 5 2009
Pavel A. Troshin
Abstract The preparation of 27 different derivatives of C60 and C70 fullerenes possessing various aryl (heteroaryl) and/or alkyl groups that are appended to the fullerene cage via a cyclopropane moiety and their use in bulk heterojunction polymer solar cells is reported. It is shown that even slight variations in the molecular structure of a compound can cause a significant change in its physical properties, in particular its solubility in organic solvents. Furthermore, the solubility of a fullerene derivative strongly affects the morphology of its composite with poly(3-hexylthiophene), which is commonly used as active material in bulk heterojunction organic solar cells. As a consequence, the solar cell parameters strongly depend on the structure and the properties of the fullerene-based material. The power conversion efficiencies for solar cells comprising these fullerene derivatives range from negligibly low (0.02%) to considerably high (4.1%) values. The analysis of extensive sets of experimental data reveals a general dependence of all solar cell parameters on the solubility of the fullerene derivative used as acceptor component in the photoactive layer of an organic solar cell. It is concluded that the best material combinations are those where donor and acceptor components are of similar and sufficiently high solubility in the solvent used for the deposition of the active layer. [source]

A new, broad-spectrum azole antifungal: posaconazole , mechanisms of action and resistance, spectrum of activity

MYCOSES, Issue 2006
H. Hof
Summary Posaconazole, a new triazole antifungal, exerts principally the same mechanism of action as the other azole derivatives, i.e. it inhibits the ergosterol production by binding and inhibiting the lanosterol-14,-demethylase which is present in almost all fungi except Pneumocystis and Pythium. Posaconazole has an exquisitely high affinity to this target. Since posaconazole has a chemical structure different from fluconazole and voriconazole, it can interact with an additional domain of the target so that it may inhibit even mutated strains resistant to fluconazole and voriconazole. In addition posaconazole is a bad substrate for efflux pumps in fungi, so it can stay active when other azoles are already inactive. Furthermore, the spectrum of posaconazole is rather large including also some zygomycetes resistant to other azoles. In conclusion, posaconazole is actually the most potent azole derivative used in medicine. A combination of posaconazole with other groups of antifungals may have a favourable effect. There are several methods to test the in vitro activities of posaconazole including the E-test, though interpretive breakpoints are still lacking. [source]

Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, Issue 3 2003
A 3D-QSAR-CoMFA method for new antiviral drug design
Abstract The predicted inhibition constant (Ki) and the predicted inhibitor concentration (IC90) of the HIV-1 protease (HIV-1 PR) inhibitors: symmetric and nonsymmetric - benzyl, ketone, oxime, pyrazole, imidazole, and triazole cyclic urea derivatives, were obtained by the 3D-CoMFA (Comparative Molecular Field Analysis) method. The CoMFA statistical parameters: cross-validate correlation coefficient (q2), higher than 0.5, and the fitted correlation coefficient (r2), higher than 0.90 validated the predicted biological activities. The best predictions were found for the trifluoromethyl ketoxime derivative (log 1/Ki predict = 8.42), the m-pyridineCH2 pyrazole derivative (log 1/Ki predict = 9.77) and the 1,2,3 triazole derivative (log 1/Ki predict = 7.03). We attempted to design a new potent HIV-1 protease inhibitor by addition of o-benzyl to the (p-HOPhCH2) pyrazole 12f derivative inhibitor. A favorable steric area surrounded the o-benzyl, suggesting a possible new potent HIV-1 protease inhibitor. [source]

Board Composition And Corporate Use Of Interest Rate Derivatives

THE JOURNAL OF FINANCIAL RESEARCH, Issue 2 2004
Kenneth A. Borokhovich
Abstract We provide new evidence on the motives for corporate hedging by examining the relation between the quality of the firms' monitoring mechanisms and the quantity of interest rate derivatives employed. Because the capital structure decision and hedging decision are considered to be endogenous, the firm's capital structure and level of interest rate derivative use are modeled simultaneously. We show a positive relation between the relative influence of outside directors and the quantity of derivatives used. This evidence indicates that outside directors take an active role in derivatives usage and that firms employ hedging in the shareholders' best interests. [source]